RxDoctor Payments Data

Aslam Khan, MD

Interventional Cardiology · Lauderdale Lakes, FLNPI 1982631750

Payments from drug & device makers

$187,257in general payments, 2019–2025

Across 43 payments — averaging $4354.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$186K
  • Abbott$338
  • Johnson & Johnson$167
  • Philips North America LLC$150
  • Boston Scientific$62
  • Merck$57
  • plus $298 from 10 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$187,257 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$33,117
Medicare patients
570
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$82,567
EntrestoSacubitril/Valsartan26$37,366
BrilintaTicagrelor13$15,255
Nifedipine ErNifedipine64$1,820
Metoprolol Succinate141$1,364
Spironolactone243$1,040
Midodrine Hcl16$799
Bumetanide18$681
Losartan Potassium120$629
Nitroglycerin33$579
Hydralazine Hcl39$490
Atorvastatin Calcium47$433
Amlodipine Besylate91$403
ClopidogrelClopidogrel Bisulfate28$315
Chlorthalidone59$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$186,184$37,36626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Lauderdale Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →